Chris Degnan
CIK 1741968 · Chief Financial Officer · last filed 2026-10-09
Chris Degnan is a Chief Financial Officer who has filed 13 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for URGN, was dated Oct 9, 2026. Across all open-market trades the lifetime net is −$53.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $231.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
URGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10 NORTH HIGH STREET, SUITE 200
WEST CHESTER, PA 19380
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| URGN | Chief Financial Officer | 6,763 | $34.04 | $230.2K | -$117.9K | 4 | 2026-10-09 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Chief Financial Officer | 50 | $17.60 | $880 | $19.6K | 6 | 2023-03-14 |
| VRCA | Chief Financial Officer | 300 | $3.42 | $1.0K | $45.0K | 2 | 2019-03-04 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-09 | URGN | Notice (144) | −2,202 | -$89.6K | EDGAR |
| 2026-10-09 | URGN | Mixed | +2,281 | -$80.8K | EDGAR |
| 2026-02-03 | URGN | Grant (A) | — | $0 | EDGAR |
| 2025-10-09 | URGN | Mixed | +2,280 | -$37.1K | EDGAR |
| 2024-10-09 | URGN | Grant (A) | — | $0 | EDGAR |
| 2023-03-14 | Galera Therapeutics, Inc. (GRTX) Delisted | Buy (P) | +10,000 | $19.6K | EDGAR |
| 2023-02-28 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-02 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-28 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-04 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.